Saturday, September 23, 2023
Saturday, September 23, 2023

Summus Raises $19.5 Million

Summus, the leading virtual health company focused in specialty care, announced today that it raised $19.5 million to support the company’s continued growth and work to solve the access problem to high quality physicians. Following a previous investment round in 2022, Summus has now raised $70 million to expand its innovative approach to care.

The company’s proprietary marketplace model empowers patients, families, caregivers and physicians to share and access high quality specialty expertise — across all health questions, at any point in the journey. By accelerating access to high quality physicians, Summus delivers best-in-class clinical guidance, advocacy and navigation. Summus works with leading employers, health plans, physician groups and leading medical institutions to provide a broad portfolio of solutions that improves access to quality care and improves outcomes.

“Durable, category defining companies naturally evolve and expand their aperture to serve more people over time. We are investing to meet the explosive demand for Summus solutions across the healthcare ecosystem,” said Mitchell Rales, Co-founder and Executive Chairman, Danaher Corporation.

In supporting more than 2 million lives, 98% of Summus members report that they better understand what to do in the next stage of their healthcare journey. Since 2020, consistent feedback from Summus members and physicians reflect universal recognition of the access and insights through Summus that would not otherwise have been available.

“The value of accessing high quality physicians in an expedient manner is vital — for peace of mind, optimizing treatment paths, and driving better outcomes. We continue our commitment to put high quality physicians, the most trusted party in healthcare, at the center of decisions big and small,” said Julian Flannery, Summus CEO and Co-founder.

The investment will focus on further scaling growth for the organization, including meeting demand for Summus’ innovative solution to support primary care physicians in a peer-to-peer environment, and enhancing condition-specific, personalized journeys for patients to access the best care with the most trusted physicians.

“We remain inspired by the Summus team and the value proposition they bring to the healthcare ecosystem. In providing access to thousands of the world’s most talented physicians to patients, families and physicians who need their expertise, we see Summus changing lives on a daily basis. We’re grateful to have the opportunity to continue to support Summus as they expand their capabilities to solve the critical issues of access to quality healthcare today,” said Rick Buhrman, Co-Founder and Co-CEO, Sator Grove Holdings. “I am impressed by the continued innovation, commitment and expertise of the Summus team, and am thrilled to see their growth and recognition in the market for bringing new solutions to physicians and patients around the world.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Lipogems® Announces 140 Independent Peer Reviewed Publications with 5 Years of Follow up in Orthopaedics

Giorgio Ninzoli, President of Lipogems International. "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."

Study Outcomes Could Provide Insights Into New Targeted Treatments to Manage this Challenging Disease

The study aims to determine if immediate biological preservation of patient-derived chordoma tumor tissue, collected intraoperatively and implanted for serial sampling in translational research, will provide new insights into the biological weakness of the disease and contribute to developing improved treatment therapies reports NICO.

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Utilizing Lunit INSIGHT MMG, an FDA-cleared and CE-marked AI solution for mammography analysis, this research backs AI's potential to replace one human reader under Europe's double reading guideline and underscores its capacity to alleviate the strain on radiologists.

MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study

SELUTION DeNovo Study is the largest DEB study ever initiated, involving up to 70 participating sites across 15 countries. Patients are randomized before any vessel preparation to reflect current medical practice and to reduce bias.  The objectives of the study are to demonstrate non-inferiority at both one and five years, and superiority for target vessel failure (TVF) at five years.

Vitestro Starts Largest-scale Clinical Trial Globally for its Autonomous Blood Drawing Device, with Enrolment of First Patients in A.D.O.P.T.

Vitestro expects to obtain CE marking by the end of 2024. The first 350 patients have currently been enrolled the A.D.O.P.T. (Autonomous Optimization and Performance Tests for Blood Testing) Trial at study site Result Laboratorium in the Albert Schweitzer Hospital. Investigational partners, in addition to Result Laboratorium - Albert Schweitzer Hospital, are St. Antonius, OLVG Lab and Amsterdam UMC.

By using this website you agree to accept Medical Device News Magazine Privacy Policy